Evidence map›Paper›PMID 34517819›Full record

ArticleBMC infectious diseases2021

Increasing integrated testing in community settings through interventions for change, including the Spring European Testing Week.

Nadia Gasbarrini, Davor Dubravić, Lauren Combs, Arian Dišković, Magdalena Ankiersztejn-Bartczak, Francesca Colaiaco, Iwona Wawer, Piotr Wysocki, Magdalena Rosińska, Anna Marzec-Boguslawska and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 5 countries.

Nadia GasbarriniFondazione Villa Maraini, Rome, Italy.
Davor DubravićCroatian Association for HIV and Viral Hepatitis (HUHIV), Zagreb, Croatia.
Lauren CombsCHIP, Centre of Excellence for Health, Immunity and Infections,, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark.
Arian DiškovićCroatian Association for HIV and Viral Hepatitis (HUHIV), Zagreb, Croatia.
Magdalena Ankiersztejn-BartczakFoundation for Social Education, Warsaw, Poland.
Francesca ColaiacoAssociazione Della Croce Rossa Italiana (CRI), Rome, Italy.
Iwona WawerNational AIDS Centre, Agency of the Ministry of Health, Warsaw, Poland.
Piotr WysockiNational AIDS Centre, Agency of the Ministry of Health, Warsaw, Poland.
Magdalena RosińskaDepartment of Epidemiology of Infectious Diseases and Surveillance, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland.
Anna Marzec-BoguslawskaNational AIDS Centre, Agency of the Ministry of Health, Warsaw, Poland.
Ben CollinsReShape/International HIV Partnerships, London, UK.
Daniel SimõesEPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
Marie Louise JakobsenCHIP, Centre of Excellence for Health, Immunity and Infections,, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark.
Dorthe RabenCHIP, Centre of Excellence for Health, Immunity and Infections,, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen Ø, Denmark. dorthe.raben@regionh.dk.
Ministry of Health · PLUniversity of Copenhagen · DKAssociazione della Croce Rossa Italiana · ITCentre of Excellence for Health, Immunity and Infections · DKFondazione Roma · ITFoundation for Polish Science · PLi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTInternational HIV/AIDS Alliance · GBNational Institute of Public Health · PL

Funding

Fundação para a Ciência e Tecnologia (FCT) PD/BD/128008/2016Gilead Sciences 03976Third Health Programme of the European Union 761319
6 · The paper itself

Abstract

backgroundMaximising access to testing by targeting more than one infection is effective in identifying new infections in settings or populations. Within the EU funded Joint Action INTEGRATE, this paper examined the feasibility and impact of expanding integrated testing for HIV, hepatitis C (HCV), chlamydia, gonorrhoea and/or syphilis in four community-based pilots through targeted interventions in Croatia, Italy and Poland and the Spring European Testing Week since community settings are key in detecting new infections and reaching key populations.

methodsPilots led by local INTEGRATE partners prioritised testing for other infections or key populations. The Croatian pilot expanded testing for men who have sex with men to syphilis, chlamydia and gonorrhoea. Italian partners implemented a HIV and HCV testing/information event at a migrant centre. A second Italian pilot tested migrants for HIV and HCV through outreach and a low-threshold service for people who use drugs. Polish partners tested for HIV, HCV and syphilis among people who inject drugs in unstable housing via a mobile van. Pilots monitored the number of individuals tested for each infection and reactive results. The pilot Spring European Testing Week from 18 to 25 May 2018 was an INTEGRATE-driven initiative to create more testing awareness and opportunities throughout Europe.

resultsThe Croatian pilot found a high prevalence for each syphilis, chlamydia and gonorrhoea respectively, 2.1%, 12.4% and 6.7%. The Italian migrant centre pilot found low proportions who were previously tested for HIV (24%) or HCV (11%) and the second Italian pilot found an HCV prevalence of 6.2%, with low proportions previously tested for HIV (33%) or HCV (31%). The Polish pilot found rates of being previously tested for HIV, HCV and syphilis at 39%, 37%, and 38%, respectively. Results from the Spring European Testing Week pilot showed it was acceptable with increased integrated testing, from 50% in 2018 to 71% in 2019 in participants.

conclusionsResults show that integrated testing is feasible and effective in community settings, in reaching key populations and minimising missed testing opportunities, and the pilots made feasible because of the European collaboration and funding. For sustainability and expansion of integrated community testing across Europe, local government investment in legislation, financial and structural support are crucial.

Indexed as

Hepatitis CHIV InfectionsSexual and Gender MinoritiesSexually Transmitted DiseasesSyphilisHomosexuality, MaleHumansMalePrevalenceCommunityHepatitisHIVIntegrated testingSexually transmitted infectionsTesting

Identifiers

PMID34517819
PMCPMC8438814
OpenAlexW3200986159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.